R&D Focusing too many R&D resources on one drug: The hidden cost... Drug development is a high-stakes, high-cost endeavour.
Events Partner Content 13th Annual Pharma Resource Planning and Portfolio Managemen... Prioritizing Projects with Tools, Data, and Governance
News Padcev/Keytruda scores again in early bladder cancer Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
